IP Library Granted Patent US 10,711,008
Granted Patent B2
US 10,711,008 · App. 16/430,234 · Granted Jul 14, 2020

Indoline analogs and uses thereof

Inventor: Stephen E. Webber (San Diego, CA)
Assignee: Oncternal Therapeutics, Inc.
C07D487/04C07D209/34C07D209/38C07D209/40C07D401/06C07D403/06C07D405/06C07D409/06C07D413/06C07D417/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,711,008
App. No.
16/430,234
Granted
Jul 14, 2020
Kind
B2
Abstract

Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.

Claims (9)

1. A compound having Formula (VII):

or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein A is selected from the group consisting of —OH, D, H, F, and —NH 2 ; wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of H, Cl, —CN, —CF 3 , C 1-6 alkyl, C 1-6 alkoxy, —C(═O)NH 2 , —NO 2 , —NH 2 , and —OH; and wherein G is selected from the group consisting of:

2. The compound of claim 1 , wherein the compound has a formula selected from the group consisting of:

3. A method for treating cancer selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head and neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer, comprising:

administering an effective amount of the compound of claim 1 to a subject in need thereof.

4. A method for killing or inhibiting the growth of a neoplastic cell, wherein the neoplastic cell is a cancer cell, the cancer being selected from the group consisting of Ewing's sarcoma, prostate cancer, glioblastoma, acute myeloid leukemia, breast cancer, head & neck cancer, melanoma, non-small cell lung cancer, ovarian cancer, and uterine cancer, comprising:

contacting the neoplastic cell with an effective amount of the compound of claim 1 .

5. A method for inhibiting proliferation of a cell, wherein the cell overexpresses an ETS gene or comprises an ETS fusion gene, comprising: contacting the cell with an effective amount of the compound of claim 1 .

6. The method of claim 5 , wherein the ETS gene or the ETS fusion gene is selected from the group consisting of FLI1, ERG, ETV1, and ETV4.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2025
From: HO’OLA THERAPEUTICS INC.
To: GEORGETOWN UNIVERSITY
Reel/Frame 071621/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2025
From: ONCTERNAL THERAPEUTICS, INC.
To: HO’OLA THERAPEUTICS INC.
Reel/Frame 071585/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2019
From: WEBBER, STEPHEN E.
To: ONCTERNAL THERAPEUTICS, INC.
Reel/Frame 049363/0041 →
Continuity (5)
Division 15680905 · Aug 18, 2017
Continuation 15461327 · Mar 16, 2017
Provisional Application 62316156 · Mar 31, 2016
Provisional Application 62417621 · Nov 4, 2016
Related Publication 20190337951A1 · Nov 7, 2019